CO5430216A1 - Composiciones que tienen estabilidad mejorada de activos farmaceuticos - Google Patents
Composiciones que tienen estabilidad mejorada de activos farmaceuticosInfo
- Publication number
- CO5430216A1 CO5430216A1 CO00001050A CO00001050A CO5430216A1 CO 5430216 A1 CO5430216 A1 CO 5430216A1 CO 00001050 A CO00001050 A CO 00001050A CO 00001050 A CO00001050 A CO 00001050A CO 5430216 A1 CO5430216 A1 CO 5430216A1
- Authority
- CO
- Colombia
- Prior art keywords
- solvent
- pharmaceutical
- composition according
- composition
- water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 13
- 239000002904 solvent Substances 0.000 abstract 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- -1 analgesic mucoItics Substances 0.000 abstract 1
- 229940035674 anesthetics Drugs 0.000 abstract 1
- 230000000954 anitussive effect Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 239000003434 antitussive agent Substances 0.000 abstract 1
- 229940124584 antitussives Drugs 0.000 abstract 1
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- 239000000850 decongestant Substances 0.000 abstract 1
- 229940124581 decongestants Drugs 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 230000003419 expectorant effect Effects 0.000 abstract 1
- 229940066493 expectorants Drugs 0.000 abstract 1
- 239000003193 general anesthetic agent Substances 0.000 abstract 1
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 abstract 1
- 238000005192 partition Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una composición oral que tiene estabilidad mejorada que comprende un activo farmacéutico y un disolvente anhídrido, hidrófilo, miscible en agua en donde el activo farmacéutico en su estado no ionizado tiene un porcentaje de valor de solubilidad en el disolvente a temperatura ambiente que es igual o superior a 0,075% y el activo farmacéutico está en forma libre no ionizada como una dispersión monomolecular en el disolvente y dicha agua en donde la cantidad de disolvente presente es desde 1 a 10%.Igualmente, se refiere al método para el suministro de la composición farmacéutica mencionada. La composición según la reivindicación 1 en donde el activo farmacéutico tiene un peso molecular inferior a 500 gramos por mol, es capaz de ser ionizado cuando está en un disolvente acuoso y tiene un coeficiente de partición octanol-agua cuando está en la forma no ionizada de por lomenos 100. La composición según la reivindicación 2 en donde el activo farmacéutico se selecciona del grupo que consiste de antitusivos, antihistaminas, antihistaminas no sedantes, descongestionantes, expectorantes, mucoIíticos analgésicos, agentes antiinflamatorios antipiréticos, anestésicos y mezclas de éstos. La composición según la reivindicación 3 en donde la concentración de activo farmacéutico en el disolvente es inferior o igual a 125% del porcentaje de valor de solubilidad del activo antes mencionado.La composición según la reivindicación 3 en donde el activo farmacéutico está presente en el disolvente a un nivel de 0,075% a 25,0% en peso de la composición.La composición según la reivindicación 5 en donde el activo farmacéutico está presente en el disolvente a un nivel de 0,28% a 10,0%. La composición según la reivindicación 1 en donde el disolvente anhídrido, hidrófilo, miscible en agua comprende de 60% a 99,975% en peso de la composición.La composición según la reivindicación 7 en donde el disolvente anhídrido, hidrófilo, miscible en agua comprende de 70% a 99% en peso de la composición.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11537899P | 1999-01-11 | 1999-01-11 | |
| US15653999P | 1999-09-29 | 1999-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5430216A1 true CO5430216A1 (es) | 2004-06-01 |
Family
ID=26813132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00001050A CO5430216A1 (es) | 1999-01-11 | 2000-01-11 | Composiciones que tienen estabilidad mejorada de activos farmaceuticos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20020086878A1 (es) |
| EP (1) | EP1143973A2 (es) |
| JP (1) | JP2002534462A (es) |
| KR (1) | KR20010093256A (es) |
| CN (1) | CN1346270A (es) |
| AU (1) | AU3344900A (es) |
| BR (1) | BR0007428A (es) |
| CA (1) | CA2360358A1 (es) |
| CO (1) | CO5430216A1 (es) |
| CZ (1) | CZ20012493A3 (es) |
| HU (1) | HUP0105279A3 (es) |
| ID (1) | ID30508A (es) |
| NO (1) | NO20013440L (es) |
| PE (1) | PE20001397A1 (es) |
| TR (1) | TR200101929T2 (es) |
| WO (1) | WO2000041692A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60309440T2 (de) | 2002-02-08 | 2007-10-11 | The Procter & Gamble Company, Cincinnati | Kindersichere verpackung |
| US20040028622A1 (en) * | 2002-08-12 | 2004-02-12 | Michael Gurin | Multifunctional flavor systems and method of use |
| AU2003299659A1 (en) | 2002-12-13 | 2004-07-09 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
| JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Ｋｄｌ株式会社 | ピリドン誘導体の溶液状医薬組成物 |
| US20070048424A1 (en) * | 2005-09-01 | 2007-03-01 | Moza Ashok K | Liquid composition of 2-Isopropyl-N,2,3-trimethylbutyramide and N-Ethyl-p-menthane-3-carboxamide, its preparation method and its applications as a cooling agent and flavor enhancer |
| US20070059417A1 (en) * | 2005-09-15 | 2007-03-15 | Moza Ashok K | Cooling agents as flavor and saltiness enhancers |
| FR2906140B1 (fr) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs |
| FR2910317B1 (fr) | 2006-12-21 | 2009-02-13 | Philippe Perovitch | Forme galenique pour l'administration par voie transmuqueuse de paracetamol |
| EP2219622A1 (en) | 2007-12-06 | 2010-08-25 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| US8518439B2 (en) * | 2008-12-03 | 2013-08-27 | Novartis Ag | Liquid therapeutic composition |
| US9572885B2 (en) | 2013-03-15 | 2017-02-21 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
| WO2018183203A1 (en) * | 2017-03-27 | 2018-10-04 | DXM Pharmaceutical, Inc. | Packaged multi-dose liquid drug formulation |
| US11234897B2 (en) | 2017-03-27 | 2022-02-01 | DXM Pharmaceutical, Inc. | Packaged multi-dose liquid dextromethorphan hydrobromide formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5100898A (en) * | 1990-01-25 | 1992-03-31 | Richardson-Vicks Inc. | Antitussive liquid compositions containing dyclonine |
| CA2181241C (en) * | 1994-01-24 | 2000-04-25 | Dadi Jamshed Dhabhar | Process for solubilizing difficultly soluble pharmaceutical actives |
| US5510389A (en) * | 1994-03-02 | 1996-04-23 | The Procter & Gamble Company | Concentrated acetaminophen solution compositions |
| US5616621A (en) * | 1995-01-30 | 1997-04-01 | American Home Products Corporation | Taste masking liquids |
-
1999
- 1999-12-20 US US09/467,334 patent/US20020086878A1/en not_active Abandoned
-
2000
- 2000-01-10 JP JP2000593303A patent/JP2002534462A/ja not_active Abandoned
- 2000-01-10 TR TR2001/01929T patent/TR200101929T2/xx unknown
- 2000-01-10 BR BR0007428-4A patent/BR0007428A/pt not_active IP Right Cessation
- 2000-01-10 CA CA002360358A patent/CA2360358A1/en not_active Abandoned
- 2000-01-10 PE PE2000000018A patent/PE20001397A1/es not_active Application Discontinuation
- 2000-01-10 CN CN00802686A patent/CN1346270A/zh active Pending
- 2000-01-10 HU HU0105279A patent/HUP0105279A3/hu unknown
- 2000-01-10 AU AU33449/00A patent/AU3344900A/en not_active Abandoned
- 2000-01-10 WO PCT/US2000/000574 patent/WO2000041692A2/en not_active Application Discontinuation
- 2000-01-10 CZ CZ20012493A patent/CZ20012493A3/cs unknown
- 2000-01-10 ID IDW00200101509A patent/ID30508A/id unknown
- 2000-01-10 KR KR1020017008797A patent/KR20010093256A/ko not_active Application Discontinuation
- 2000-01-10 EP EP00911569A patent/EP1143973A2/en not_active Withdrawn
- 2000-01-11 CO CO00001050A patent/CO5430216A1/es not_active Application Discontinuation
-
2001
- 2001-07-11 NO NO20013440A patent/NO20013440L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1143973A2 (en) | 2001-10-17 |
| CN1346270A (zh) | 2002-04-24 |
| WO2000041692A3 (en) | 2000-11-30 |
| AU3344900A (en) | 2000-08-01 |
| BR0007428A (pt) | 2002-10-15 |
| JP2002534462A (ja) | 2002-10-15 |
| US20020086878A1 (en) | 2002-07-04 |
| CZ20012493A3 (cs) | 2001-11-14 |
| TR200101929T2 (tr) | 2001-12-21 |
| NO20013440L (no) | 2001-09-11 |
| HUP0105279A3 (en) | 2003-05-28 |
| NO20013440D0 (no) | 2001-07-11 |
| CA2360358A1 (en) | 2000-07-20 |
| KR20010093256A (ko) | 2001-10-27 |
| HUP0105279A2 (hu) | 2002-05-29 |
| ID30508A (id) | 2001-12-13 |
| PE20001397A1 (es) | 2000-12-21 |
| WO2000041692A2 (en) | 2000-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5270007A1 (es) | Composiciones que tienen suministro mejorado de activos | |
| CO5430216A1 (es) | Composiciones que tienen estabilidad mejorada de activos farmaceuticos | |
| ES2229626T3 (es) | Composiciones antimicrobianas basadas en alcohol con apariencia cosmetica. | |
| ES2587869T3 (es) | Composición oftálmica de olopatadina de concentración alta | |
| PE20010627A1 (es) | Composiciones que tienen estabilidad mejorada | |
| DK1553927T3 (da) | Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger | |
| ATE376423T1 (de) | Gelierende wässrige pharmazeutische zusammensetzungen | |
| BG106439A (en) | Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative | |
| ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
| BRPI0406905B8 (pt) | composição de distribuição tópica em um recipiente pressurizado | |
| RU2015137145A (ru) | Новые жидкие композиции с повышенной стабильностью | |
| TW434023B (en) | Preserved ophthalmic composition | |
| ES2184310T3 (es) | Formulacion autoemulsionante para compuestos lipofilos acidos. | |
| AR058619A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
| WO2010130028A1 (en) | Compositions suitable for the topical treatment of fungal infections of the skin and nails | |
| BR0317340A (pt) | Formulações de hfc em solução contendo tiotrópio | |
| AR044861A1 (es) | Una composicion para pelicula consumible via oral para suministrar agentes antiplaca y refrescantes del aliento | |
| BR0309057A (pt) | Formulações lìquidas com baixa dosagem em entecavir e uso | |
| CL2004001325A1 (es) | Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas. | |
| ES2240492T3 (es) | Soluciones de ibuprofeno para rellenar capsulas y preparaciones de capsulas. | |
| PE20001424A1 (es) | Composiciones que tienen estabilidad mejorada | |
| BR0215303A (pt) | Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol | |
| HUP9801712A2 (hu) | Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása | |
| AU2008322739B2 (en) | Use of anti-bacterial compounds having an anaesthetic effect | |
| ES2531241T3 (es) | Composición farmacéutica líquida estable a base de trazodona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |